Side effects and toxicities of targeted therapies in stage IV melanoma.
Identifieur interne : 00E281 ( Main/Exploration ); précédent : 00E280; suivant : 00E282Side effects and toxicities of targeted therapies in stage IV melanoma.
Auteurs : Paolo A. Ascierto [France] ; Lars Bastholt ; Peter Hersey ; Gabriela Cinat ; Alexander M M. Eggermont ; Axel Hauschild ; Enrique Espinosa ; Caroline RobertSource :
- American journal of therapeutics [ 1536-3686 ]
Descripteurs français
- KwdFr :
- Antinéoplasiques (effets indésirables), Antinéoplasiques (pharmacologie), Conception de médicament, Facteurs immunologiques (effets indésirables), Facteurs immunologiques (pharmacologie), Humains, Inhibiteurs de protéines kinases (effets indésirables), Inhibiteurs de protéines kinases (pharmacologie), Mélanome (anatomopathologie), Mélanome (traitement médicamenteux), Stade de la tumeur, Thérapie moléculaire ciblée, Tumeurs cutanées (anatomopathologie), Tumeurs cutanées (traitement médicamenteux).
- MESH :
- anatomopathologie : Mélanome, Tumeurs cutanées.
- effets indésirables : Antinéoplasiques, Facteurs immunologiques, Inhibiteurs de protéines kinases.
- pharmacologie : Antinéoplasiques, Facteurs immunologiques, Inhibiteurs de protéines kinases.
- traitement médicamenteux : Mélanome, Tumeurs cutanées.
- Conception de médicament, Humains, Stade de la tumeur, Thérapie moléculaire ciblée.
English descriptors
- KwdEn :
- Antineoplastic Agents (adverse effects), Antineoplastic Agents (pharmacology), Drug Design, Humans, Immunologic Factors (adverse effects), Immunologic Factors (pharmacology), Melanoma (drug therapy), Melanoma (pathology), Molecular Targeted Therapy, Neoplasm Staging, Protein Kinase Inhibitors (adverse effects), Protein Kinase Inhibitors (pharmacology), Skin Neoplasms (drug therapy), Skin Neoplasms (pathology).
- MESH :
- chemical , adverse effects : Antineoplastic Agents, Immunologic Factors, Protein Kinase Inhibitors.
- chemical , pharmacology : Antineoplastic Agents, Immunologic Factors, Protein Kinase Inhibitors.
- drug therapy : Melanoma, Skin Neoplasms.
- pathology : Melanoma, Skin Neoplasms.
- Drug Design, Humans, Molecular Targeted Therapy, Neoplasm Staging.
Abstract
As the incidence of melanoma continues to increase worldwide, the search for new therapies for advanced (stage IV) melanoma brings with it new patterns of toxicity to contend with. This review covers the toxicity profiles of new treatments for advanced melanoma currently in development. Therefore, the latest literature on melanoma treatment was surveyed for data on reported toxicities. The new types of treatments can be roughly divided into targeted tyrosine kinase inhibitors and immunomodulating agents. Each has its own set of toxicities particular to type and to individual drug. Targeted tyrosine kinase inhibitors generally cause fatigue, whereas immunomodulatory agents induce a specific set of adverse events known as immune-related adverse events (irAEs). Despite the incidence of adverse events, these agents hold promise for the treatment of stage IV melanoma. With new treatment opportunities come increased chance of toxic reactions. The key to successful melanoma treatment in the future is likely to be novel combinations of new therapeutic agents.
DOI: 10.1097/MJT.0b013e3182a39858
PubMed: 24185314
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 003145
- to stream PubMed, to step Curation: 003049
- to stream PubMed, to step Checkpoint: 003049
- to stream Ncbi, to step Merge: 001551
- to stream Ncbi, to step Curation: 001551
- to stream Ncbi, to step Checkpoint: 001551
- to stream Main, to step Merge: 00F521
- to stream Main, to step Curation: 00E281
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Side effects and toxicities of targeted therapies in stage IV melanoma.</title><author><name sortKey="Ascierto, Paolo A" sort="Ascierto, Paolo A" uniqKey="Ascierto P" first="Paolo A" last="Ascierto">Paolo A. Ascierto</name><affiliation wicri:level="1"><nlm:affiliation>1Unit of Melanoma, Cancer Immunotherapy and Innovative Therapy, Istituto Nazionale Tumori-Fondazione G. Pascale, Naples, Italy; 2Odense University Hospital, Odense, Denmark; 3Newcastle University, Newcastle, Australia; 4Instituto de Oncologia Angel Rolfo, Buenos Aires, Argentina; 5Institut Gustave Roussy, Villejuif, France; 6University of Kiel, Kiel, Germany; 7Hospital La Paz, Madrid, Spain; and 8Institut Gustave Roussy, Villejuif, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>1Unit of Melanoma, Cancer Immunotherapy and Innovative Therapy, Istituto Nazionale Tumori-Fondazione G. Pascale, Naples, Italy; 2Odense University Hospital, Odense, Denmark; 3Newcastle University, Newcastle, Australia; 4Instituto de Oncologia Angel Rolfo, Buenos Aires, Argentina; 5Institut Gustave Roussy, Villejuif, France; 6University of Kiel, Kiel, Germany; 7Hospital La Paz, Madrid, Spain; and 8Institut Gustave Roussy, Villejuif</wicri:regionArea><wicri:noRegion>Villejuif</wicri:noRegion><wicri:noRegion>Villejuif</wicri:noRegion></affiliation></author><author><name sortKey="Bastholt, Lars" sort="Bastholt, Lars" uniqKey="Bastholt L" first="Lars" last="Bastholt">Lars Bastholt</name></author><author><name sortKey="Hersey, Peter" sort="Hersey, Peter" uniqKey="Hersey P" first="Peter" last="Hersey">Peter Hersey</name></author><author><name sortKey="Cinat, Gabriela" sort="Cinat, Gabriela" uniqKey="Cinat G" first="Gabriela" last="Cinat">Gabriela Cinat</name></author><author><name sortKey="Eggermont, Alexander M M" sort="Eggermont, Alexander M M" uniqKey="Eggermont A" first="Alexander M M" last="Eggermont">Alexander M M. Eggermont</name></author><author><name sortKey="Hauschild, Axel" sort="Hauschild, Axel" uniqKey="Hauschild A" first="Axel" last="Hauschild">Axel Hauschild</name></author><author><name sortKey="Espinosa, Enrique" sort="Espinosa, Enrique" uniqKey="Espinosa E" first="Enrique" last="Espinosa">Enrique Espinosa</name></author><author><name sortKey="Robert, Caroline" sort="Robert, Caroline" uniqKey="Robert C" first="Caroline" last="Robert">Caroline Robert</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="????"><PubDate><MedlineDate>2015 Jan-Feb</MedlineDate></PubDate></date><idno type="RBID">pubmed:24185314</idno><idno type="pmid">24185314</idno><idno type="doi">10.1097/MJT.0b013e3182a39858</idno><idno type="wicri:Area/PubMed/Corpus">003145</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">003145</idno><idno type="wicri:Area/PubMed/Curation">003049</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">003049</idno><idno type="wicri:Area/PubMed/Checkpoint">003049</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">003049</idno><idno type="wicri:Area/Ncbi/Merge">001551</idno><idno type="wicri:Area/Ncbi/Curation">001551</idno><idno type="wicri:Area/Ncbi/Checkpoint">001551</idno><idno type="wicri:Area/Main/Merge">00F521</idno><idno type="wicri:Area/Main/Curation">00E281</idno><idno type="wicri:Area/Main/Exploration">00E281</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Side effects and toxicities of targeted therapies in stage IV melanoma.</title><author><name sortKey="Ascierto, Paolo A" sort="Ascierto, Paolo A" uniqKey="Ascierto P" first="Paolo A" last="Ascierto">Paolo A. Ascierto</name><affiliation wicri:level="1"><nlm:affiliation>1Unit of Melanoma, Cancer Immunotherapy and Innovative Therapy, Istituto Nazionale Tumori-Fondazione G. Pascale, Naples, Italy; 2Odense University Hospital, Odense, Denmark; 3Newcastle University, Newcastle, Australia; 4Instituto de Oncologia Angel Rolfo, Buenos Aires, Argentina; 5Institut Gustave Roussy, Villejuif, France; 6University of Kiel, Kiel, Germany; 7Hospital La Paz, Madrid, Spain; and 8Institut Gustave Roussy, Villejuif, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>1Unit of Melanoma, Cancer Immunotherapy and Innovative Therapy, Istituto Nazionale Tumori-Fondazione G. Pascale, Naples, Italy; 2Odense University Hospital, Odense, Denmark; 3Newcastle University, Newcastle, Australia; 4Instituto de Oncologia Angel Rolfo, Buenos Aires, Argentina; 5Institut Gustave Roussy, Villejuif, France; 6University of Kiel, Kiel, Germany; 7Hospital La Paz, Madrid, Spain; and 8Institut Gustave Roussy, Villejuif</wicri:regionArea><wicri:noRegion>Villejuif</wicri:noRegion><wicri:noRegion>Villejuif</wicri:noRegion></affiliation></author><author><name sortKey="Bastholt, Lars" sort="Bastholt, Lars" uniqKey="Bastholt L" first="Lars" last="Bastholt">Lars Bastholt</name></author><author><name sortKey="Hersey, Peter" sort="Hersey, Peter" uniqKey="Hersey P" first="Peter" last="Hersey">Peter Hersey</name></author><author><name sortKey="Cinat, Gabriela" sort="Cinat, Gabriela" uniqKey="Cinat G" first="Gabriela" last="Cinat">Gabriela Cinat</name></author><author><name sortKey="Eggermont, Alexander M M" sort="Eggermont, Alexander M M" uniqKey="Eggermont A" first="Alexander M M" last="Eggermont">Alexander M M. Eggermont</name></author><author><name sortKey="Hauschild, Axel" sort="Hauschild, Axel" uniqKey="Hauschild A" first="Axel" last="Hauschild">Axel Hauschild</name></author><author><name sortKey="Espinosa, Enrique" sort="Espinosa, Enrique" uniqKey="Espinosa E" first="Enrique" last="Espinosa">Enrique Espinosa</name></author><author><name sortKey="Robert, Caroline" sort="Robert, Caroline" uniqKey="Robert C" first="Caroline" last="Robert">Caroline Robert</name></author></analytic><series><title level="j">American journal of therapeutics</title><idno type="eISSN">1536-3686</idno></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Antineoplastic Agents (adverse effects)</term><term>Antineoplastic Agents (pharmacology)</term><term>Drug Design</term><term>Humans</term><term>Immunologic Factors (adverse effects)</term><term>Immunologic Factors (pharmacology)</term><term>Melanoma (drug therapy)</term><term>Melanoma (pathology)</term><term>Molecular Targeted Therapy</term><term>Neoplasm Staging</term><term>Protein Kinase Inhibitors (adverse effects)</term><term>Protein Kinase Inhibitors (pharmacology)</term><term>Skin Neoplasms (drug therapy)</term><term>Skin Neoplasms (pathology)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Antinéoplasiques (effets indésirables)</term><term>Antinéoplasiques (pharmacologie)</term><term>Conception de médicament</term><term>Facteurs immunologiques (effets indésirables)</term><term>Facteurs immunologiques (pharmacologie)</term><term>Humains</term><term>Inhibiteurs de protéines kinases (effets indésirables)</term><term>Inhibiteurs de protéines kinases (pharmacologie)</term><term>Mélanome (anatomopathologie)</term><term>Mélanome (traitement médicamenteux)</term><term>Stade de la tumeur</term><term>Thérapie moléculaire ciblée</term><term>Tumeurs cutanées (anatomopathologie)</term><term>Tumeurs cutanées (traitement médicamenteux)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Antineoplastic Agents</term><term>Immunologic Factors</term><term>Protein Kinase Inhibitors</term></keywords><keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en"><term>Antineoplastic Agents</term><term>Immunologic Factors</term><term>Protein Kinase Inhibitors</term></keywords><keywords scheme="MESH" qualifier="anatomopathologie" xml:lang="fr"><term>Mélanome</term><term>Tumeurs cutanées</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Melanoma</term><term>Skin Neoplasms</term></keywords><keywords scheme="MESH" qualifier="effets indésirables" xml:lang="fr"><term>Antinéoplasiques</term><term>Facteurs immunologiques</term><term>Inhibiteurs de protéines kinases</term></keywords><keywords scheme="MESH" qualifier="pathology" xml:lang="en"><term>Melanoma</term><term>Skin Neoplasms</term></keywords><keywords scheme="MESH" qualifier="pharmacologie" xml:lang="fr"><term>Antinéoplasiques</term><term>Facteurs immunologiques</term><term>Inhibiteurs de protéines kinases</term></keywords><keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Mélanome</term><term>Tumeurs cutanées</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Drug Design</term><term>Humans</term><term>Molecular Targeted Therapy</term><term>Neoplasm Staging</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Conception de médicament</term><term>Humains</term><term>Stade de la tumeur</term><term>Thérapie moléculaire ciblée</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">As the incidence of melanoma continues to increase worldwide, the search for new therapies for advanced (stage IV) melanoma brings with it new patterns of toxicity to contend with. This review covers the toxicity profiles of new treatments for advanced melanoma currently in development. Therefore, the latest literature on melanoma treatment was surveyed for data on reported toxicities. The new types of treatments can be roughly divided into targeted tyrosine kinase inhibitors and immunomodulating agents. Each has its own set of toxicities particular to type and to individual drug. Targeted tyrosine kinase inhibitors generally cause fatigue, whereas immunomodulatory agents induce a specific set of adverse events known as immune-related adverse events (irAEs). Despite the incidence of adverse events, these agents hold promise for the treatment of stage IV melanoma. With new treatment opportunities come increased chance of toxic reactions. The key to successful melanoma treatment in the future is likely to be novel combinations of new therapeutic agents.</div></front></TEI><affiliations><list><country><li>France</li></country></list><tree><noCountry><name sortKey="Bastholt, Lars" sort="Bastholt, Lars" uniqKey="Bastholt L" first="Lars" last="Bastholt">Lars Bastholt</name><name sortKey="Cinat, Gabriela" sort="Cinat, Gabriela" uniqKey="Cinat G" first="Gabriela" last="Cinat">Gabriela Cinat</name><name sortKey="Eggermont, Alexander M M" sort="Eggermont, Alexander M M" uniqKey="Eggermont A" first="Alexander M M" last="Eggermont">Alexander M M. Eggermont</name><name sortKey="Espinosa, Enrique" sort="Espinosa, Enrique" uniqKey="Espinosa E" first="Enrique" last="Espinosa">Enrique Espinosa</name><name sortKey="Hauschild, Axel" sort="Hauschild, Axel" uniqKey="Hauschild A" first="Axel" last="Hauschild">Axel Hauschild</name><name sortKey="Hersey, Peter" sort="Hersey, Peter" uniqKey="Hersey P" first="Peter" last="Hersey">Peter Hersey</name><name sortKey="Robert, Caroline" sort="Robert, Caroline" uniqKey="Robert C" first="Caroline" last="Robert">Caroline Robert</name></noCountry><country name="France"><noRegion><name sortKey="Ascierto, Paolo A" sort="Ascierto, Paolo A" uniqKey="Ascierto P" first="Paolo A" last="Ascierto">Paolo A. Ascierto</name></noRegion></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 00E281 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 00E281 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Asie
|area= AustralieFrV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:24185314
|texte= Side effects and toxicities of targeted therapies in stage IV melanoma.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:24185314" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a AustralieFrV1
| This area was generated with Dilib version V0.6.33. |  |